In a study of 109 triple negative breast cancer patients whose primary breast tumor was evaluated for GAL‐9+ immune cells, the authors found high GAL‐9 was significantly associated with higher levels of stromal TILs, PD‐L1 positive tumor cells and negative PD‐L1 immune cells. This evidence concerns the gene LGALS9 and neoplasm.